title: Use of Biologics in Sjögren's Syndrome.
abstract: The management of patients suffering from primary Sjögren syndrome (pSS) has long been mainly symptomatic and demonstration of effectiveness of systemic drugs was lacking. However, progress made in the understanding of pSS pathogenesis has allowed moving into a more targeted approach to therapeutic intervention. Given the key role of chronic B-cell activation, B-cell target therapies were the first candidates. New pathways are currently being investigated, including costimulation and ectopic germinal center. In this review, we summarize the current evidence regarding B-cell targeted and anti-TNF therapies and provide an overview of promising drugs in the pipeline.
authors.affiliation: INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, rue Gabriel Peri, 94270 Le Kremlin-Bicêtre, France; Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, rue du générale Leclerc, 94270 Le Kremlin-Bicêtre, France.
authors.forename: Gaetane
authors.initials: G
authors.lastname: Nocturne
authors.affiliation: Department of Rheumatology, CHRU Brest, rue Boulevard Tanguy Prigent, 29609 Brest, France; EA 2216, INSERM ESPRI, ERI29, Université de Brest, LabEx IGO, 5 Foch - CHU Morvan - BP 824, 29609 Brest, France.
authors.forename: Divi
authors.initials: D
authors.lastname: Cornec
authors.affiliation: INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, rue Gabriel Peri, 94270 Le Kremlin-Bicêtre, France; Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, rue du générale Leclerc, 94270 Le Kremlin-Bicêtre, France.
authors.forename: Raphaèle
authors.initials: R
authors.lastname: Seror
authors.affiliation: INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, rue Gabriel Peri, 94270 Le Kremlin-Bicêtre, France; Department of Rheumatology, AP-HP, Hôpitaux Universitaires Paris-Sud, rue du générale Leclerc, 94270 Le Kremlin-Bicêtre, France. Electronic address: xavier.mariette@aphp.fr.
authors.forename: Xavier
authors.initials: X
authors.lastname: Mariette
mesh_terms: D000069594:Abatacept / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D000068800:Etanercept / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab / Q000627:therapeutic use; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D000069283:Rituximab / Q000627:therapeutic use; D012859:Sjogren's Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D001688:Biological Products; D007166:Immunosuppressive Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D014409:Tumor Necrosis Factor-alpha; C448700:epratuzumab; D000069283:Rituximab; C511911:belimumab; D000069594:Abatacept; D000069285:Infliximab; C502936:tocilizumab; D000068800:Etanercept
keywords: Biological treatment; B cell; Clinical trials; Outcome measure; Primary Sjögren’s syndrome